Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 6;141(14):1768-1772.
doi: 10.1182/blood.2022018896.

Validation of the Molecular International Prognostic Scoring System in patients with myelodysplastic syndromes

Tariq Kewan  1   2 , Waled Bahaj  1 , Arda Durmaz  1   3 , Mai Aly  1   4 , Olisaemeka D Ogbue  1 , Hetty E Carraway  1 , Mikkael A Sekeres  5 , Valeria Visconte  1 , Carmelo Gurnari  1   6 , Jaroslaw P Maciejewski  1
Affiliations

Validation of the Molecular International Prognostic Scoring System in patients with myelodysplastic syndromes

Tariq Kewan et al. Blood. .

Erratum in

No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
Baseline characteristics of the validation cohort. (A) Characteristics of the validation cohort as compared with the original and the validation cohorts of the IPSS-M study. (B) Cross heat map for distribution of patients with MDS according to the IPSS-R (x-axis) and the IPSS-M (y-axis) scores. (C) Bar histogram shows the total percentage of patients restratified (upstaged or downstaged) according to the IPSS-M. CC, Cleveland Clinic cohort; CMML, chronic myelomonocytic leukemia; EB, MDS with excess blast; Hb, hemoglobin; IQR, interquartile range; IWG-M, International Working Group for the Prognosis of MDS Cohort; J-MDS, Japanese validation cohort; MLD, multilineage dysplasia; MPN, myeloproliferative neoplasm; Plt, platelet; RS-T, ring sideroblast-thrombocytosis; SLD, single lineage dysplasia; U, unspecified; WHO, World Health Organization.
Figure 2.
Figure 2.
Comparison of the IPSS-M and IPSS-R. (A) Stratification of our cohort based on IPSS-M for OS, LFS, and PFS. (B) Model discrimination measured by the concordance index via bootstrapping for the IPSS-R (light blue) and the IPSS-M system (red) across all the 3 outcomes end points (LFS, OS, and PFS) for the full cohort, treated vs untreated patients, males vs females, and ≥60 vs <60 years old. (C) The cumulative AUC differences (ΔAUC) based on IPSS-M between treated and untreated patients (y-axis) is plotted against the follow-up time intervals of 10 months (x-axis).
See this image and copyright information in PMC

References

    1. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079–2088. - PubMed
    1. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454–2465. - PMC - PubMed
    1. Voso MT, Gurnari C. Have we reached a molecular era in myelodysplastic syndromes? Hematology Am Soc Hematol Educ Program. 2021;2021(1):418–427. - PMC - PubMed
    1. Nagata Y, Zhao R, Awada H, et al. Machine learning demonstrates that somatic mutations imprint invariant morphologic features in myelodysplastic syndromes. Blood. 2020;136(20):2249–2262. - PMC - PubMed
    1. Haferlach T, Nagata Y, Grossmann V, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014;28(2):241–247. - PMC - PubMed